Top

Published in:

01-02-2010 | Preclinical Study

RETRACTED ARTICLE: Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways

Authors: C. Buchanan, I. Stigliano, H. M. Garay-Malpartida, L. Rodrigues Gomes, L. Puricelli, M. C. Sogayar, E. Bal de Kier Joffé, M. G. Peters

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Abstract

Glypican-3 (GPC3) is a proteoglycan involved in proliferation and cell survival. Several reports demonstrated that GPC3 is downregulated in some tumors, such as breast cancer. Previously, we determined that GPC3 reexpression in the murine mammary adenocarcinoma LM3 cells induced an impairment of their invasive and metastatic capacities, associated with a decrease of their motility and an increase of their cell death. We demonstrated that GPC3 inhibits canonical Wnt signaling, as well as it activates non canonical pathway. Now, we identified signaling pathways responsible for the pro-apoptotic role of GPC3 in LM3 cells. We found for the first time that GPC3 inhibits the PI3K/Akt anti-apoptotic pathway while it stimulates the p38MAPK stress-activated one. We report a concomitant modulation of CDK inhibitors as well as of pro- and anti-apoptotic molecules. Our results provide new clues regarding the mechanism involved in the modulation induced by GPC3 of mammary tumor cell growth and survival.

Filmus J, Selleck SB (2001) Glypicans: proteoglycans with a surprise. J Clin Invest 108:497–501CrossRefPubMedPubMedCentral

Nakato H, Futch TA, Selleck SB (1995) The division abnormally delayed (dally) gene: a putative integral membrane proteoglycan required for cell division pattering during postembryonic development of the nervous system in Drosophila. Development 121:3687–3702CrossRefPubMed

Baeg GH, Lin X, Khare N, Baumgartner S, Perrimon N (2001) Heparan sulfate proteoglycans are critical for the organization of the extracellular distribution of Wingless. Development 126:87–94CrossRef

Cano-Gauci DF, Song HH, Yang H, McKerlie C, Choo B, Shi W, Pullano R, Piscione TD, Grisaru S, Soon S, Sedlackova L, Tanswell AK, Mak TW, Yeger H, Lockwood GA, Rosenblum ND, Filmus J (1999) Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol 146:255–264PubMedPubMedCentral

Chiao E, Fisher P, Crisponi L, Deiana M, Dragatsis I, Schlessinger D, Pilia G, Efstratiadis A (2002) Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling. Dev Biol 243:185–206. doi:10.1006/dbio.2001.0554 CrossRefPubMed

Garganta CL, Bodurtha JN (1992) Report of another family with Simpson-Golabi-Behmel syndrome and a review of the literature. Am J Med Genet 44:129–135. doi:10.1002/ajmg.1320440202 CrossRefPubMed

Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D (1996) Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 12:241–247. doi:10.1038/ng0396-241 CrossRefPubMed

Dueñas-Gonzalez A, Kaya M, Shi W, Song H, Test JR, Penn LZ, Filmus J (1998) OCI 5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell-specific manner. J Cell Biol 141:1407–1414. doi:10.1083/jcb.141.6.1407 CrossRef

Lin H, Huber R, Schlessinger D, Morin PJ (1999) Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 59:807–810PubMed

10.

Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J, Testa JR (2000) Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 19:410–416. doi:10.1038/sj.onc.1203322 CrossRefPubMed

11.

Xiang YY, Ladeda V, Filmus J (2001) Glypican-3 expression is silenced in human breast cancer. Oncogene 20:7408–7412. doi:10.1038/sj.onc.1204925 CrossRefPubMed

12.

Peters MG, Farias E, Colombo L, Filmus J, Puricelli L, Bal de Kier Joffe E (2003) Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat 80:221–232. doi:10.1023/A:1024549729256 CrossRefPubMed

13.

Weksberg R, Squire JA, Templeton DM (1996) Glypicans: a growing trend. Nat Genet 12:225–227. doi:10.1038/ng0396-225 CrossRefPubMed

14.

Song HH, Shi W, Filmus J (1997) OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem 272:7574–7577. doi:10.1074/jbc.272.12.7574 CrossRefPubMed

15.

16.

Capurro MI, Xiang YY, Lobe C, Filmus J (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65:6245–6254. doi:10.1158/0008-5472.CAN-04-4244 CrossRefPubMed

17.

Song HH, Shi W, Xiang YY, Filmus J (2005) The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 280:2116–2125. doi:10.1074/jbc.M410090200 CrossRefPubMed

18.

Stigliano I, Puricelli L, Filmus J, Sogayar MC, Bal de Kier Joffe E, Peters MG (2008) Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat 114:251–262. doi:10.1007/s10549-008-0009-2 CrossRefPubMed

19.

Urtreger A, Ladeda V, Puricelli L, Rivelli A, Vidal MC, Lustig ES, Bal de Kier Joffé E (1997) Modulation of fibronectin expression and proteolytic activity associated with the invasive and metastatic phenotype in two murine mammary cell lines. Int J Oncol 11:489–496PubMed

20.

Bal de Kier Joffé E, Puricelli L, Vidal MC, Lustig ES (1983) Characterization of two murine mammary adenocarcinoma tumors with different metastatic ability. J Exp Clin Cancer Res 2:151–160

21.

Mizushima S, Nagata S (1990) pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 18:5322. doi:10.1093/nar/18.17.5322 CrossRefPubMedPubMedCentral

22.

Filmus J, Shi W, Wong ZM, Wong MJ (1995) Identification of a new membrane-bound heparan sulphate proteoglycan. Biochem J 311(Pt 2):561–565CrossRefPubMedPubMedCentral

23.

Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254. doi:10.1016/0003-2697(76)90527-3 CrossRefPubMed

24.

Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45. doi:10.1093/nar/29.9.e45 CrossRefPubMedPubMedCentral

25.

Mitsiades CS, Mitsiades N, Koutsilieris M (2004) The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 4:235–256. doi:10.2174/1568009043333032 CrossRefPubMed

26.

Gonzalez AD, Kaya M, Shi W, Song H, Testa JR, Penn LZ, Filmus J (1998) OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 141:1407–1414. doi:10.1083/jcb.141.6.1407 CrossRefPubMedPubMedCentral

27.

Berger JC, Vander Griend D, Stadler WM, Rinker-Schaeffer C (2004) Metastasis suppressor genes: signal transduction, cross-talk and the potential for modulating the behavior of metastatic cells. Anticancer Drugs 15:559–568. doi:10.1097/01.cad.0000132233.36512.fa CrossRefPubMed

28.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70. doi:10.1016/S0092-8674(00)81683-9 CrossRefPubMed

29.

30.

Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7:683–694. doi:10.1016/S1097-2765(01)00214-3 CrossRefPubMed

31.

Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2:594–604. doi:10.1038/nrc864 CrossRefPubMed

32.

Platanias LC (2003) Map kinase signaling pathways and hematologic malignancies. Blood 101:4667–4679. doi:10.1182/blood-2002-12-3647 CrossRefPubMed

33.

Baldwin AS Jr (2001) Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107:3–6. doi:10.1172/JCI11891 CrossRefPubMedPubMedCentral

34.

Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A (2005) Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 20:539–550. doi:10.1016/j.molcel.2005.10.033 CrossRefPubMed

35.

Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911–1912. doi:10.1126/science.1072682 CrossRefPubMed

36.

Huang J, Wu L, Tashiro S, Onodera S, Ikejima T (2005) Bcl-2 up-regulation and P-p53 down-regulation account for the low sensitivity of murine L929 fibrosarcoma cells to oridonin-induced apoptosis. Biol Pharm Bull 28:2068–2074. doi:10.1248/bpb.28.2068 CrossRefPubMed

37.

She QB, Chen N, Dong Z (2000) ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem 275:20444–20449. doi:10.1074/jbc.M001020200 CrossRefPubMed

38.

Baeg GH, Perrimon N (2000) Functional binding of secreted molecules to heparan sulfate proteoglycans in Drosophila. Curr Opin Cell Biol 12:575–580. doi:10.1016/S0955-0674(00)00134-4 CrossRefPubMed

39.

Katoh M (2005) WNT/PCP signaling pathway and human cancer. Oncol Rep 14:1583–1588 (review)PubMed

40.

Kuriyama M, Harada N, Kuroda S, Yamamoto T, Nakafuku M, Iwamatsu A, Yamamoto D, Prasad R, Croce C, Canaani E, Kaibuchi K (1996) Identification of AF-6 and canoe as putative targets for Ras. J Biol Chem 271:607–610. doi:10.1074/jbc.271.2.607 CrossRefPubMed

41.

Cuadrado A, Lafarga V, Cheung PC, Dolado I, Llanos S, Cohen P, Nebreda AR (2007) A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis. EMBO J 26:2115–2126. doi:10.1038/sj.emboj.7601657 CrossRefPubMedPubMedCentral

Title: RETRACTED ARTICLE: Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways
Authors: C. Buchanan
I. Stigliano
H. M. Garay-Malpartida
L. Rodrigues Gomes
L. Puricelli
M. C. Sogayar
E. Bal de Kier Joffé
M. G. Peters
Publication date: 01-02-2010
Publisher: Springer New York
Published in: Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0362-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer

Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy

Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer

A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?

Impact of menopausal symptoms on quality of life 6 months after systemic breast cancer treatment: results from the Shanghai Breast Cancer Survival Study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer